Digital pathology firm Aignostics raised $34 million in series B funding, which it plans to use to fuel its growth in the U.S. and develop new models.
The oversubscribed round was led by ATHOS, with investments from the Mayo Clinic; HTGF; and additional participation from existing investors Wellington Partners, Boehringer Ingelheim Venture Fund, CARMA Fund, and VC Fonds Technologie, managed by IBB Ventures.
In a statement, the Berlin-based Aignostics said that the latest funding round brings the company's total funding to over $55 million, which will be used to develop the firm's offerings for target ID, translational research, and companion diagnostics (CDx). In addition, the funding will help advance several initiatives, including the firm's continued expansion into the U.S.; the launch of scaled "plug-and-play" products for a range of indications and tasks, such as tumor microenvironment and biomarker profiling; and collaborative development of foundation models and biopharma product offerings with the Mayo Clinic.
Aignostics, founded in 2018 as a spinoff from the Berlin Institute of Health at Charité, uses artificial intelligence to create models that support drug discovery, translational research, clinical trials, and CDx development.
